Stock listing
NYSE:MANE Veradermics, Incorporated Stock
Home listing (NYSE) of Veradermics, Incorporated
Follow Veradermics, Incorporated into a list and get an email when it puts out news.
Share price · NYSE:MANE
$119.52 USD -5.34 (-4.3%)
Close on Nov 20, 2026
- Day range
- $118.99 – $123.70 USDNov 20, 2026
- Volume
- 374,921 sharesNov 20, 2026
- Market cap
- $5.04B USDAt the close on Nov 20, 2026 · price × 42.20M shares outstanding
- Traded on an average day
- $88.38M USDMedian day 623,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:MANE · Home | $119.52 USD | -5.34 (-4.3%) | 374,921 | $121.98 | $123.70 | $118.99 | $124.86 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:MANE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $119.52 | -5.34 | -4.3% | $121.98 | $123.70 | $118.99 | 374,921 | |
| $124.86 | -0.78 | -0.6% | $127.60 | $127.68 | $122.98 | 265,259 | |
| $125.64 | -2.41 | -1.9% | $128.00 | $129.81 | $124.48 | 400,801 | |
| $128.05 | -1.61 | -1.2% | $131.66 | $131.94 | $127.32 | 487,646 | |
| $129.66 | -5.63 | -4.2% | $134.06 | $136.97 | $128.24 | 937,783 | |
| $135.29 | -21.27 | -13.6% | $146.66 | $147.54 | $133.92 | 2,305,377 | |
| $156.56 | +8.12 | +5.5% | $148.74 | $156.60 | $146.81 | 697,760 | |
| $148.44 | +4.49 | +3.1% | $141.81 | $152.82 | $141.81 | 599,209 | |
| $143.95 | +5.17 | +3.7% | $138.06 | $145.47 | $131.39 | 491,919 | |
| $138.78 | +10.18 | +7.9% | $130.93 | $139.89 | $130.00 | 500,253 | |
| $128.60 | -7.91 | -5.8% | $136.20 | $136.50 | $125.40 | 788,054 | |
| $136.51 | +2.90 | +2.2% | $136.51 | $138.66 | $130.51 | 561,949 | |
| $133.61 | +4.08 | +3.1% | $131.02 | $138.48 | $131.02 | 536,271 | |
| $129.53 | -10.16 | -7.3% | $139.00 | $139.72 | $128.94 | 635,534 | |
| $139.69 | -4.16 | -2.9% | $141.79 | $145.41 | $138.33 | 464,764 | |
| $143.85 | +0.02 | 0.0% | $141.96 | $146.58 | $140.19 | 513,422 | |
| $143.83 | +3.11 | +2.2% | $139.17 | $144.26 | $137.68 | 397,213 | |
| $140.72 | +3.33 | +2.4% | $136.84 | $141.08 | $136.76 | 466,648 | |
| $137.39 | -1.39 | -1.0% | $136.74 | $140.80 | $136.67 | 392,381 | |
| $138.78 | +0.29 | +0.2% | $139.44 | $139.93 | $134.49 | 423,100 | |
| $138.49 | +1.83 | +1.3% | $136.00 | $141.75 | $135.14 | 794,100 | |
| $136.66 | +9.55 | +7.5% | $127.50 | $139.12 | $127.14 | 706,900 | |
| $127.11 | +4.83 | +3.9% | $120.62 | $130.11 | $113.52 | 1,068,700 | |
| $122.28 | +13.46 | +12.4% | $115.34 | $123.93 | $113.00 | 1,463,900 | |
| $108.82 | -6.25 | -5.4% | $114.19 | $114.25 | $106.51 | 672,900 | |
| $115.07 | +1.60 | +1.4% | $112.74 | $115.99 | $111.05 | 688,900 | |
| $113.47 | -2.79 | -2.4% | $115.35 | $118.91 | $112.62 | 484,600 | |
| $116.26 | -6.14 | -5.0% | $121.17 | $122.27 | $115.67 | 845,100 | |
| $122.40 | -8.50 | -6.5% | $129.99 | $129.99 | $120.57 | 991,400 | |
| $130.90 | +4.27 | +3.4% | $125.71 | $135.12 | $123.02 | 1,113,900 | |
| $126.63 | +15.68 | +14.1% | $111.60 | $136.72 | $110.56 | 3,489,900 | |
| $110.95 | +1.99 | +1.8% | $108.92 | $113.43 | $108.84 | 655,100 | |
| $108.96 | -9.91 | -8.3% | $119.29 | $119.29 | $108.77 | 736,723 | |
| $118.87 | +2.11 | +1.8% | $116.45 | $119.12 | $114.80 | 536,363 | |
| $116.76 | -0.46 | -0.4% | $120.26 | $120.85 | $115.48 | 598,300 | |
| $117.22 | -4.01 | -3.3% | $121.23 | $123.83 | $116.04 | 659,800 | |
| $121.23 | +3.41 | +2.9% | $117.56 | $122.44 | $116.76 | 689,400 | |
| $117.82 | +2.82 | +2.5% | $115.34 | $118.94 | $112.03 | 481,700 | |
| $115.00 | -1.57 | -1.3% | $114.57 | $118.00 | $112.30 | 633,500 | |
| $116.57 | +0.85 | +0.7% | $116.00 | $118.15 | $113.88 | 613,600 | |
| $115.72 | -0.06 | -0.1% | $115.29 | $117.91 | $111.51 | 580,700 | |
| $115.78 | -2.36 | -2.0% | $118.11 | $118.74 | $110.60 | 753,800 | |
| $118.14 | +5.34 | +4.7% | $113.99 | $122.00 | $113.22 | 2,135,900 | |
| $112.80 | +6.05 | +5.7% | $107.44 | $113.24 | $105.40 | 583,600 | |
| $106.75 | -1.93 | -1.8% | $109.30 | $109.30 | $104.54 | 1,870,200 | |
| $108.68 | +6.26 | +6.1% | $105.56 | $109.74 | $102.83 | 766,500 | |
| $102.42 | -1.47 | -1.4% | $103.86 | $104.93 | $100.50 | 860,200 | |
| $103.89 | +2.19 | +2.2% | $102.02 | $105.26 | $100.01 | 938,800 | |
| $101.70 | +2.73 | +2.8% | $99.31 | $104.19 | $98.46 | 620,700 | |
| $98.97 | +0.83 | +0.8% | $99.45 | $102.29 | $98.82 | 576,000 | |
| $98.14 | -1.53 | -1.5% | $98.96 | $99.86 | $97.04 | 394,400 | |
| $99.67 | -4.16 | -4.0% | $103.20 | $104.53 | $97.00 | 552,600 | |
| $103.83 | +5.32 | +5.4% | $99.00 | $104.23 | $98.17 | 712,800 | |
| $98.51 | +0.76 | +0.8% | $98.92 | $99.89 | $97.20 | 363,000 | |
| $97.75 | -0.71 | -0.7% | $99.74 | $100.98 | $95.42 | 356,200 | |
| $98.46 | +0.95 | +1.0% | $97.80 | $100.55 | $95.44 | 427,200 | |
| $97.51 | -0.90 | -0.9% | $98.59 | $100.86 | $97.27 | 548,300 | |
| $98.41 | +0.48 | +0.5% | $100.00 | $101.38 | $97.14 | 678,500 | |
| $97.93 | -3.88 | -3.8% | $102.30 | $102.41 | $97.00 | 623,500 | |
| $101.81 | -0.99 | -1.0% | $102.06 | $103.44 | $100.39 | 270,800 | |
| $102.80 | +0.45 | +0.4% | $102.04 | $104.87 | $101.30 | 657,000 | |
| $102.35 | +3.89 | +4.0% | $100.31 | $104.08 | $97.73 | 787,163 | |
| $98.46 | -4.36 | -4.2% | $100.00 | $102.75 | $93.81 | 717,278 | |
| $102.82 | -2.50 | -2.4% | $105.18 | $108.87 | $102.52 | 393,600 | |
| $105.32 | -5.91 | -5.3% | $111.00 | $111.39 | $101.69 | 773,100 |
- Ticker
- NYSE:MANE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Veradermics to Present at the Jefferies Global Healthcare Conference in London
Latest deck · Nov 9, 2026
Corporate Update (November 2026)
Corporate update · 54 slides
Latest news
Veradermics to Present at the Jefferies Global Healthcare Conference in London
Nov 12, 2026
Closed $129.66 (-4.2%) on Nov 13, 2026
Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Nov 10, 2026
Closed $148.44 (+3.1%) on Nov 10, 2026
Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss
Nov 9, 2026
Closed $143.95 (+3.7%) on Nov 9, 2026
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Nov 8, 2026
Closed $143.95 (+3.7%) on Nov 9, 2026
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
Oct 19, 2026
Closed $122.28 (+12.4%) on Oct 19, 2026
Veradermics to Present at Upcoming September Investor Conferences
Sep 3, 2026
Closed $98.51 (+0.8%) on Sep 4, 2026
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Aug 11, 2026
Closed $108.95 (-1.6%) on Aug 11, 2026
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Jul 17, 2026
Closed $111.32 (+5.2%) on Jul 17, 2026
Veradermics, Incorporated on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 25 in all · newest Nov 12, 2026 · oldest 2026
- Decks
- 7 decks · latest Nov 9, 2026
Where Veradermics, Incorporated is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:MANE · Home listing · This page | NYSE | United States | USD |
| BX Swiss:MANE | BX Swiss | Switzerland | CHF |
| BOATS:MANE | BOATS | United States | USD |
Valuation
Price/book 6.3× against a median of 6.6×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.25B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 6.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.13
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Veradermics, Incorporated · NYSE:MANE | US$5.04B | US$4.25B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.13 |
| Belite Bio, Inc. · NASDAQ:BLTE | US$5.13B | US$5.13B | n/a | n/a | n/a | 6.6× | n/a | 0.0× | 1.34 |
| SK Biopharmaceuticals Co., Ltd. · KRX:326030 | US$5.08B | US$4.80B | 16.9× | 7.5× | 20.1× | 6.7× | 46.6% | 0.0× | n/a |
| Liquidia Corporation · NASDAQ:LQDA | US$4.90B | US$4.68B | n/a | 7.5× | n/a | n/a | −15.2% | n/a | 0.84 |
| Erasca, Inc. · NASDAQ:ERAS | US$4.78B | US$4.18B | n/a | n/a | n/a | 5.2× | n/a | 0.1× | 1.51 |
| Dianthus Therapeutics, Inc. · NASDAQ:DNTH | US$4.76B | US$3.92B | n/a | 1,444× | n/a | 3.8× | n/a | 0.0× | 0.90 |
| PTC Therapeutics, Inc. · NASDAQ:PTCT | US$4.71B | US$3.12B | n/a | 2.7× | n/a | n/a | −9.2% | n/a | 0.88 |
| Cogent Biosciences, Inc. · NASDAQ:COGT | US$4.65B | US$4.08B | n/a | n/a | n/a | 9.0× | n/a | 0.4× | 1.30 |
| Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSA | US$4.53B | US$3.97B | 41.4× | 4.2× | 29.9× | 6.4× | 11.6% | 0.0× | 0.57 |
| Travere Therapeutics, Inc. · NASDAQ:TVTX | US$4.51B | US$4.21B | n/a | 6.5× | n/a | 200× | −18.7% | 0.0× | 1.31 |
| Ionis Pharmaceuticals, Inc. · NASDAQ:IONS | US$4.43B | US$4.70B | n/a | 4.9× | n/a | 11.3× | −56.9% | 5.5× | 0.40 |
| Median of the others | US$4.74B | US$4.19B | 29.2× | 6.5× | 25.0× | 6.6× | −12.2% | 0.0× | 0.90 |
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 178.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.87 · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Reid Waldman | Chief Executive Officer and Board Member |
| Dominic Carrano | Chief Financial Officer and Treasurer |
| Michael Greco | General Counsel |
| David A. Hollander | Chief R&D Officer |
| Mark Neumann | Chief Commercial and Strategy Officer |
| Tim Durso | Chief Technical Officer |
Board
| Director | Role |
|---|---|
| John W. Childs | Chairman |
| David Friedman | Board Member |
| Jane Grant-Kels | Board Member |
| Katarina Pance | Board Member |
| Patrick Enright | Board Member |
| Reid Waldman | Chief Executive Officer and Board Member |
| Vlad Coric | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +5.5% |
| Q2 2026 | Aug 11, 2026 · After close | +0.1% |
| Q1 2026 | May 15, 2026 · After close | +0.7% |
| Q4 2025 | Mar 30, 2026 · After close | +3.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 54 slides | Nov 9, 2026 |
| Corporate Update (October 2026) | Corporate update | 50 slides | Oct 19, 2026 |
| Investor Presentation (September 2026) | Investor deck | 69 slides | September 2026 |
| Technical Presentation (July 2026) | Technical | 41 slides | Jul 15, 2026 |
| Technical Presentation (July 2026) | Technical | 41 slides | July 2026 |
| Technical Presentation (April 2026) | Technical | 39 slides | Apr 27, 2026 |
| Technical Presentation (April 2026) | Technical | 39 slides | April 2026 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: about US$384.4M · US$100 a share · Jefferies +6 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Citigroup (co-lead), Cantor (co-lead), LifeSci, Needham & Company, LifeSci Capital | Apr 30, 2026 |
| Private placement of pre-funded warrants Update: about US$30M · US$100 a share · Jefferies +5 Dealers: Jefferies, Leerink Partners, Citigroup, Cantor, LifeSci Capital, Needham & Company Buyers: Suvretta Capital (certain affiliated entities buying 300,000 pre-funded warrants) | Apr 30, 2026 |
| Public offering of common stock Closed: US$294.8M raised · US$17 a share · Jefferies +3 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Citigroup (co-lead), Cantor (co-lead) | Feb 5, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Feb 3, 2026.
- Price
- US$17.00 a share
- Shares offered
- 15,077,647 shares of common stock
- Offering size
- US$256.3 million
- Underwriters' option
- Up to 2,261,647 more shares
- Listing
- MANE on the New York Stock Exchange
- Underwriters
- Jefferies, Leerink Partners, Citigroup, Cantor · In the order on the cover
- Shares delivered
- On or about Feb 5, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 27, 2025 |
| Filed publicly | Jan 9, 2026 |
| Amended once | Jan 28, 2026 |
| Declared effective by the SEC | Jan 30, 2026 |
| Shares registered with an exchange | Feb 3, 2026 |
| Final prospectus, with the price | Feb 4, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 4, 2026 |
| CERT · Exchange's certificate of listing | Feb 4, 2026 |
| S-1MEF · Registration of more shares for the same offering | Feb 3, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 3, 2026 |
| FWP · Free writing prospectus | Feb 3, 2026 |
| EFFECT · Notice that a registration is effective | Jan 30, 2026 |
| S-1/A · Registration statement, amended | Jan 28, 2026 |
| S-1 · Registration statement | Jan 9, 2026 |
| DRS · Draft registration statement | Oct 27, 2025 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 4, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Research and development | 62.1M | 23.3M | 15.0M |
| Selling, general and administrative | 10.3M | 3.50M | 2.35M |
| Operating income | -72.3M | -26.8M | -17.3M |
| Interest expense | 0 | 585.0K | 36.0K |
| Income before tax | -70.0M | -26.5M | -16.5M |
| Income tax | 0 | 0 | |
| Net income | -70.0M | -26.5M | -16.5M |
| Earnings per share, basic | -111.91 | -37.05 | -0.08 |
| Earnings per share, diluted | -111.91 | -37.05 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | 21.8M | 53.1M | 16.3M |
| Short-term investments | 120.1M | 0 | |
| Receivables | 1.25M | 1.38M | |
| Current assets | 152.5M | 55.5M | 17.6M |
| Property, plant and equipment | 22.0K | 0 | |
| Total assets | 152.6M | 55.5M | 18.5M |
| Accounts payable | 2.13M | 2.25M | 1.85M |
| Current liabilities | 9.15M | 4.72M | 3.05M |
| Long-term debt | 786.0K | ||
| Total debt | 4.00K | 786.0K | |
| Total liabilities | 9.16M | 4.72M | 3.84M |
| Shareholders' equity | -121.0M | -48.5M | 14.6M |
| Shares outstanding | 749.8K | 736.9K | 201.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash from operations | -71.6M | -23.7M | -13.5M |
| Capital spending | -24.0K | 0 | 0 |
| Free cash flow | -71.6M | -23.7M | -13.5M |
| Cash from investing | -118.9M | 0 | |
| Cash from financing | 159.1M | 60.5M | 13.9M |
| Change in cash | -31.3M | 36.8M | 385.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
All 104 filings
Cap table
Built by 6ix from Veradermics, Incorporated’s releases · as of Nov 5, 2026
- Common shares
- 42,195,472
- Fully diluted
- 42,195,472
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 42,195,472 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 42,195,472 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Vlad Coric Other companies: Royalty Pharma plc (Director · Since at least Apr 7, 2025); Biohaven Ltd. (Chairman & Chief Executive Officer · Since at least Sep 22, 2022); Revance Therapeutics, Inc. (Director · Mar 1, 2023 – Feb 4, 2025 · Past); Akili Inc (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Biohaven Pharmaceutical Holding Co Ltd (Chief Executive Officer, Director · May 3, 2017 – Oct 3, 2022 · Past) | Board Member · Since at least Feb 3, 2026 |
| John W. Childs Other companies: Biohaven Ltd. (Director · Since at least Sep 28, 2022); Biohaven Pharmaceutical Holding Co Ltd (Director · Mar 22, 2019 – Oct 3, 2022 · Past) | Chairman · Since at least Feb 3, 2026 |
| Aaron Cowen Other companies: Benitec Biopharma Inc. (Director · Since at least Sep 26, 2024) | Director · Since at least Feb 4, 2026 |
| David Friedman Other companies: Benitec Biopharma Inc. (Director · Since at least Mar 25, 2025) | Board Member · Since at least Nov 5, 2026 |
| Mark Neumann Other companies: Intra-Cellular Therapies Inc (EVP, Chief Commercial Officer · Oct 15, 2018 – Apr 2, 2025 · Past) | Chief Commercial Officer · Since at least Feb 3, 2026 |
| Patrick G. Enright Other companies: Jazz Pharmaceuticals plc (Managing Director, Longitude Capital · Since at least Aug 5, 2026) | Board Member · Since at least Nov 5, 2026 |
| Reid Waldman Other companies: Achieve Life Sciences, Inc. (Director · Since at least May 29, 2026) | Chief Executive Officer and Board Member · Since at least Feb 3, 2026 |
| David A. Hollander | Chief R&D Officer · Since at least Sep 1, 2026 |
| Dominic Carrano | Chief Financial Officer and Treasurer · Since at least Nov 4, 2026 |
| Jane Grant-Kels | Board Member · Since at least Feb 3, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Katarina Pance | Board Member · Since at least Feb 3, 2026 |
| Mark Neumann | Chief Commercial and Strategy Officer · Since at least Mar 30, 2026 |
| Michael Greco | General Counsel · Since at least Nov 4, 2026 |
| Tim Durso | Chief Technical Officer · Since at least Aug 18, 2026 |
Log in to ask 6ix AI your own questions about Veradermics, Incorporated.